Advanced search
Publication Cover
Drug, Healthcare and Patient Safety Volume 7, 2015 - Issue
Submit an article Journal homepage
104
Views
16
CrossRef citations to date
0
Altmetric
Review

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis

Alberto Gajofatto1 Department of Neurological, Biomedical and Movement Sciences, University of Verona, Verona, Italy;2 Division of Neurology B, Verona University Hospital, Verona, ItalyCorrespondence[email protected]
,
Marco Turatti2 Division of Neurology B, Verona University Hospital, Verona, Italy
,
Salvatore Monaco1 Department of Neurological, Biomedical and Movement Sciences, University of Verona, Verona, Italy;2 Division of Neurology B, Verona University Hospital, Verona, Italy
&
Maria Donata Benedetti2 Division of Neurology B, Verona University Hospital, Verona, Italy
Pages 157-167 | Published online: 11 Dec 2015

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Alberto Gajofatto & Marco Turatti. (2018) Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs 27:3, pages 273-286.
Read now
Alberto Gajofatto. (2017) Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Design, Development and Therapy 11, pages 3153-3157.
Read now
Alberto Gajofatto, Marco Turatti & Maria Donata Benedetti. (2017) Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. Expert Review of Neurotherapeutics 17:4, pages 393-406.
Read now
Emanuele D’Amico, Aurora Zanghì & Francesco Patti. (2016) Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Review of Precision Medicine and Drug Development 1:4, pages 353-360.
Read now

Articles from other publishers (12)

Qian Han, Hua-zheng Tang, Min Zou, Jie Zhao, Ling Wang, Zhao-xiang Bian & Yan-hong Li. (2020) Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models. Journal of Natural Products 83:6, pages 1939-1949.
Crossref
Pushpinder Kaur, Alana Lewis, Abdul Basit, Nikolas St Cyr & Zaman Muhammad. (2020) Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod. IDCases 22, pages e00961.
Crossref
Mehrdokht Mazdeh, Shahriar Kargar Monhaser, Mohammad Taheri & Soudeh Ghafouri‐Fard. (2019) A non‐randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing‐remitting multiple sclerosis patients. Clinical and Translational Medicine 8:1.
Crossref
Sterling B. Ortega, Poornima Pandiyan, Jana Windsor, Vanessa O. Torres, Uma M. Selvaraj, Amy Lee, Michael Morriss, Fenghua Tian, Lakshmi Raman & Ann M. Stowe. (2019) A Pilot Study Identifying Brain-Targeting Adaptive Immunity in Pediatric Extracorporeal Membrane Oxygenation Patients With Acquired Brain Injury. Critical Care Medicine 47:3, pages e206-e213.
Crossref
Gabriel Pardo & David E. Jones. (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. Journal of Neurology 264:12, pages 2351-2374.
Crossref
Alejandro Enriquez-Marulanda, Jaime Valderrama-Chaparro, Laura Parrado, Juan Diego Vélez, Ana Maria Granados, Jorge Luis Orozco & Jairo Quiñones. (2017) Cerebral toxoplasmosis in an MS patient receiving Fingolimod. Multiple Sclerosis and Related Disorders 18, pages 106-108.
Crossref
Hong Jiang, Yuanyuan Zhang, Kewei Tian, Beibei Wang & Shu Han. (2017) Amelioration of experimental autoimmune encephalomyelitis through transplantation of placental derived mesenchymal stem cells. Scientific Reports 7:1.
Crossref
Ke-Wei Tian, Fan Zhang, Hong Jiang, Beibei Wang & Shu Han. (2017) Role of C16, angiopoietin-1 and regeneration gene protein 2 in attenuating inflammation in an experimental rat model of autoimmune encephalomyelitis. Journal of Anatomy 230:1, pages 30-46.
Crossref
Emanuele D’Amico, Aurora Zanghì, Carmela Leone, Hayrettin Tumani & Francesco Patti. (2016) Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Safety 39:12, pages 1163-1174.
Crossref
Ralf A. Linker & Guillaume Wendt. (2016) Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Neurology and Therapy 5:2, pages 193-201.
Crossref
Loredana La Mantia, Irene Tramacere, Belal Firwana, Ilaria Pacchetti, Roberto Palumbo & Graziella Filippini. (2016) Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2016:4.
Crossref
Calvin J. Meaney & Spinel Karas. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 407 424 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.